Clinical trial · no report yet · Phase 3
ASCENT-03
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299 ↗
- Active not recruiting
- Gilead Sciences
- 281 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 126 | |
| YouTube | 85 | |
| Podcasts | 63 | |
| X videos | 7 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Triple Negative Breast Cancer; PD-L1 Negative
- Interventions
- Sacituzumab Govitecan-hziy; Paclitaxel; nab-Paclitaxel; Gemcitabine; Carboplatin
- Arms
- Sacituzumab Govitecan-hziy (SG) · Experimental
- Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 623
- Primary outcomes
- Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Sponsor
- Gilead Sciences
- Start
- Jul 20, 2022
- Primary completion
- Jul 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05382299 · updated Apr 6, 2026
Publications
linked from the registry- Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. PubMed 41124233